An MPNRF Patient Impact Council recently launched to actively advocate for the patient voice and perspective in all aspects of our work to promote research

Thrive Award Spotlight : Iannis Aifantis, PhD “Our work has previously focused on other types of blood cancer, including myeloid and lymphoid leukemias,” says Iannis

As of November 6th, 2023, the MPN Research Foundation has opened the MPN Challenge™ funding cycle. Please click here for further details on eligibility, proposal

MPN Research Foundation is pleased to share the news of the US FDA approval of momelotinib for the treatment of myelofibrosis patients with anemia whether they have

“From the outset, we recognized that outstanding care of MPN patients required not just hematologists (who would be their primary doctors) but also the participation

Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood